7 of 26 trials
in patients with IC

Antiplatelet agents reduced all cause
(RR, 0.76; 95% CI, 0.60-0.98),
cardiovascular mortality (RR, 0.54;
95% CI, 0.32-0.93), and the risk of
needing revascularization (RR, 0.65;
95% CI, 